Focusing on the crowded SERD space left little room for differentiation

Genetic therapies compete in the same indications, as degraders come of age

In BioCentury’s Public Equity Report: Oncology companies tap public markets for more than $1.2B, while Olema draws $250M PIPE for Novartis combo trial

Plus: Simcere grows Massachusetts presence, and updates from Eisai, Bliss, Eccogene, Phathom, Ironwood and more

Plus: FDA approves Jaypirca, Lilly’s non-covalent Btk inhibitor and updates from Novartis, Legend, Goldfinch Bio and Relive

AstraZeneca’s camizestrant data cap progress in oral SERDs, a class that is figuring out how to demonstrate benefit against changing competition

BioCentury’s roundup of translational news

BVF Partners, TCG Crossover co-lead funding to advance Plexium’s cell- and DEL-based degrader discovery tech 

Nextech Invest leads $85M series A to make the difficult-to-drug protein class amenable to small molecules

Elacestrant meets Phase III endpoints, rewarding Menarini’s appetite for risk